{"gene":"FOXR2","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2014,"finding":"FoxR2 was identified as an oncogene in medulloblastoma through a transposon mutagenesis screen; FoxR2 overexpression transformed NIH3T3 cells and promoted proliferation of granule neuron precursor (GNP) cells. FoxR2, along with Tgif2 and Alx4, activated Gli-binding sites in cooperation with Gli1, placing FoxR2 functionally within the SHH signaling pathway.","method":"Transposon-based insertional mutagenesis screen in mouse brain; NIH3T3 transformation assay; GNP proliferation assay; Gli-luciferase reporter assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays (transformation, proliferation, reporter) in a single study with in vivo genetic screen validation","pmids":["24599127"],"is_preprint":false},{"year":2016,"finding":"FOXR2 forms a stable protein complex with MYC and MAX and promotes MYC's transcriptional activities, thereby regulating cell proliferation. This interaction was identified via large-scale proteomic analysis of the human transcription factor interaction network and validated functionally.","method":"Proteomic interaction network analysis (Co-IP/MS); functional proliferation assays; xenograft tumor growth assay with FOXR2 knockdown","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP/proteomic identification of MYC/MAX complex, combined with functional knockdown and in vivo xenograft validation in a single study","pmids":["27346356"],"is_preprint":false},{"year":2016,"finding":"FOXR2 knockdown in hepatocellular carcinoma cells reduced cell growth and colony formation, and FOXR2 overexpression promoted xenograft tumor growth. β-catenin, Skp2, c-Myc, and Gli-1 were identified as downstream effectors of FOXR2 in regulation of cell proliferation by qRT-PCR.","method":"RNA interference knockdown; colony formation assay; xenograft mouse model; qRT-PCR of downstream effectors","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — clean KD/OE with defined cellular phenotype and downstream marker profiling, single lab, no direct biochemical pathway placement","pmids":["26846213"],"is_preprint":false},{"year":2017,"finding":"In glioma cells, FoxR2 overexpression increased MMP-2 level and activity and decreased expression and nuclear accumulation of p27, promoting cell proliferation and invasion. FoxR2 knockout induced G1 arrest with decreased cyclin D1, cyclin E, and p-Rb levels.","method":"FoxR2 overexpression and knockout in glioma cell lines; Western blot for cyclin D1, cyclin E, p-Rb, p27, MMP-2; cell cycle analysis; migration/invasion assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — defined cellular phenotype with multiple molecular readouts, single lab, no direct mechanistic reconstitution","pmids":["28915588"],"is_preprint":false},{"year":2017,"finding":"FOXR2 knockdown in prostate cancer cells down-regulated β-catenin, cyclinD1, and c-Myc protein levels, indicating FOXR2 promotes proliferation and invasion at least in part through the Wnt/β-catenin signaling pathway.","method":"RNA interference knockdown; Western blot; in vitro proliferation, migration, invasion assays; in vivo xenograft","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — defined phenotype with pathway marker validation, single lab, no direct reconstitution","pmids":["28068638"],"is_preprint":false},{"year":2017,"finding":"FOXR2 was identified as a direct target of miR-202 in endometrial adenocarcinoma by luciferase reporter assay; miR-202 re-expression suppressed cell proliferation and reduced FOXR2 protein levels.","method":"TargetScan prediction; luciferase reporter assay; Western blot; qRT-PCR; in vitro and in vivo proliferation assays","journal":"Disease markers","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct 3'UTR luciferase validation of miR-202 targeting of FOXR2, single lab","pmids":["28827892"],"is_preprint":false},{"year":2017,"finding":"FOXR2 knockdown in colorectal cancer cells reduced proliferation, invasion, EMT, and decreased Shh, Gli1, and Ptch1 protein expression, placing FOXR2 upstream of the Hedgehog signaling pathway in CRC.","method":"RNA interference; Western blot of Shh pathway components; in vitro invasion/EMT assays; in vivo xenograft","journal":"Oncology research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — defined pathway marker changes with KD phenotype, single lab","pmids":["28548041"],"is_preprint":false},{"year":2018,"finding":"FOXR2 knockdown inhibited non-small cell lung cancer cell proliferation and invasion, and reduced protein levels of β-catenin, cyclinD1, and c-Myc, indicating FOXR2 activates the Wnt/β-catenin pathway in NSCLC.","method":"RNA interference; Western blot; in vitro proliferation/invasion assays; in vivo xenograft","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — defined phenotype with pathway marker readout, single lab","pmids":["29634928"],"is_preprint":false},{"year":2019,"finding":"Foxr2 overexpression in a Trp53-deficient mouse background caused formation of CNS-embryonal tumors in olfactory bulb and brainstem. Early proliferative lesions expanded Olig2+ cells. Tumor-derived cells formed spheres in vitro and recapitulated parental tumors upon transplantation, confirming tumor-initiating cell properties.","method":"Transgenic mouse model (Foxr2 overexpression + Trp53 knockout); histological analysis; sphere formation assay; transplantation assay; gene expression profiling","journal":"Neuro-oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with multiple orthogonal validations (histology, sphere assay, transplantation, transcriptomics)","pmids":["30976792"],"is_preprint":false},{"year":2019,"finding":"The lncRNA HOTAIR negatively regulates miR-152, which directly targets FOXR2 3'UTR at two binding sites (validated by luciferase reporter assay). Knockdown of FOXR2 inhibited prostate cancer cell proliferation and promoted apoptosis.","method":"Luciferase reporter assay (two miR-152 binding sites on FOXR2 3'UTR); qRT-PCR; microRNA chip; CCK8/flow cytometry","journal":"Zhonghua yi xue za zhi","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct 3'UTR binding validated, functional KD phenotype shown, single lab","pmids":["31269585"],"is_preprint":false},{"year":2020,"finding":"FOXR2 knockdown in thyroid cancer cells inhibited hypoxia-induced ROS production and migration/invasion, with the Hedgehog pathway implicated as a downstream effector mechanism.","method":"RNA interference; ROS measurement; migration/invasion assays; Hedgehog pathway inhibitor experiments","journal":"Clinical and experimental pharmacology & physiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single-method KD with partial pathway implication and no direct biochemical reconstitution","pmids":["32068268"],"is_preprint":false},{"year":2021,"finding":"FOXR2 binds and stabilizes MYCN protein in neuroblastoma cells; FOXR2 knockdown reduced MYCN protein levels, caused cell cycle arrest, reduced cell growth, and induced cell death in FOXR2-expressing neuroblastoma cell lines.","method":"Immunoprecipitation (FOXR2-MYCN); FOXR2 knockdown in neuroblastoma cell lines; Western blot for MYCN protein; cell cycle and growth assays; transcriptome analysis","journal":"Journal of clinical oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP demonstrating FOXR2-MYCN binding, combined with KD phenotype and transcriptome profiling, validated in patient tumor samples","pmids":["34110923"],"is_preprint":false},{"year":2021,"finding":"E3 ubiquitin ligase PJA1 promotes ubiquitin-mediated proteasomal degradation of FOXR2 in lung adenocarcinoma cells. Forced PJA1 expression inhibited cell invasion and induced apoptosis through inactivation of the Wnt/β-catenin signaling pathway.","method":"Co-expression studies; Western blot; ubiquitination assay; in vitro invasion and apoptosis assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — ubiquitination assay identifying PJA1 as E3 ligase for FOXR2, functional consequences shown, single lab","pmids":["33839405"],"is_preprint":false},{"year":2022,"finding":"FOXR2 is epigenetically activated in cancer through hypomethylation of a novel alternative promoter. This novel promoter was functionally validated as necessary for FOXR2 expression and proliferation in FOXR2-expressing cancer cells. FOXR2 co-opted ETS family transcription circuits across multiple cancer lineages.","method":"Pan-cancer DNA methylation analysis; promoter methylation functional validation; FOXR2 knockdown with proliferation readout; transcriptional circuit analysis across >10,000 cancer samples","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional promoter validation combined with pan-cancer epigenetic profiling and mechanistic ETS circuit characterization across multiple cancer types","pmids":["35802025"],"is_preprint":false},{"year":2022,"finding":"CircANKRD17 interacts with the RNA-binding protein FUS to stabilize FOXR2 mRNA/protein in ovarian cancer, promoting PTX resistance. This was demonstrated by RNA pull-down and RNA immunoprecipitation assays.","method":"RNA pull-down; RNA immunoprecipitation (RIP); qRT-PCR; Western blot; CCK-8; flow cytometry; xenograft","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct pull-down demonstrating circANKRD17-FUS-FOXR2 axis, single lab","pmids":["36107285"],"is_preprint":false},{"year":2004,"finding":"Human FOXN6 (FOXR2) was identified as containing a forkhead (FOX) domain (codons 167-248) and a novel N-terminal FN56 domain (codons 1-69) conserved among FOXN6 and FOXN5 orthologs. The gene is located at chromosome Xp11.21, clustered with RRAGB and KLF8.","method":"Bioinformatics/in silico analysis; sequence alignment; phylogenetic analysis","journal":"International journal of oncology","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only, no functional validation","pmids":["15202009"],"is_preprint":false},{"year":2024,"finding":"FOXR2 overexpression in human embryonic stem cell-derived medial ganglionic eminence (MGE) progenitors activated the MEK/ERK signaling pathway through suppression of the endogenous RAS inhibitor DIRAS3, promoting proliferation and in vivo tumorigenicity. MEK inhibitor trametinib preferentially suppressed proliferation of FOXR2-expressing MGE progenitors.","method":"Human embryonic stem cell differentiation model; FOXR2 overexpression; transcriptome analysis; MEK/ERK pathway Western blot; MEK inhibitor (trametinib) treatment; in vivo tumorigenicity assay","journal":"Neuro-oncology advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway placement (FOXR2→DIRAS3 suppression→MEK/ERK activation) validated in a novel stem cell model with functional inhibitor confirmation and in vivo tumorigenicity","pmids":["39220247"],"is_preprint":false},{"year":2025,"finding":"FOXR2 binding on chromatin in murine models revealed association with ETS transcriptional networks and direct binding at transcription factors coordinating initiation of gliogenesis. In vivo prenatal Foxr2 targeting to ganglionic eminences in mice induced postnatal cortical tumors recapitulating NB-FOXR2 molecular signatures.","method":"ChIP/FOXR2 chromatin binding profiling in murine models; in vivo prenatal Foxr2 targeting (electroporation/viral); single-cell transcriptomics; integration with normal brain single-cell reference atlas","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct chromatin binding profiling combined with in vivo genetic modeling and single-cell transcriptomics, multiple orthogonal methods","pmids":["39495206"],"is_preprint":false}],"current_model":"FOXR2 is a forkhead transcription factor (with a canonical FOX domain and a conserved N-terminal FN56 domain, located at Xp11.21) that functions as a pan-cancer oncogene: it is epigenetically activated through hypomethylation of a novel alternative promoter, forms a stable complex with MYC/MAX to potentiate MYC transcriptional activity, binds and stabilizes MYCN protein in neuroblastoma, activates ETS transcriptional circuits and the MEK/ERK pathway (by suppressing the RAS inhibitor DIRAS3), and engages the SHH, Wnt/β-catenin, and Hedgehog pathways downstream; its protein stability is regulated by PJA1-mediated ubiquitin–proteasomal degradation, and in vivo it drives CNS-embryonal tumor formation originating from LHX6+/DLX+ medial ganglionic eminence progenitors."},"narrative":{"mechanistic_narrative":"FOXR2 is a forkhead transcription factor that functions as a pan-cancer oncogene, transforming cells and driving proliferation across diverse lineages including CNS-embryonal tumors, neuroblastoma, and multiple carcinomas [PMID:24599127, PMID:27346356, PMID:35802025]. Its central oncogenic mechanism is the potentiation of MYC-family transcription factors: FOXR2 forms a stable complex with MYC and MAX to enhance MYC transcriptional activity [PMID:27346356], and in neuroblastoma it binds and stabilizes MYCN protein, with FOXR2 loss reducing MYCN levels and triggering cell-cycle arrest and death [PMID:34110923]. FOXR2 is aberrantly switched on in cancer through hypomethylation of a novel alternative promoter, and once expressed it co-opts ETS-family transcriptional circuits to sustain proliferation [PMID:35802025]; chromatin-binding profiles confirm association with ETS networks and direct binding at transcription factors that initiate gliogenesis [PMID:39495206]. Functionally it activates the MEK/ERK pathway by suppressing the endogenous RAS inhibitor DIRAS3, rendering FOXR2-expressing progenitors sensitive to MEK inhibition [PMID:39220247]. In vivo, FOXR2 overexpression in a Trp53-deficient background or prenatal targeting to the ganglionic eminences generates CNS-embryonal/cortical tumors that recapitulate NB-FOXR2 molecular signatures, identifying medial ganglionic eminence progenitors as a cell of origin [PMID:30976792, PMID:39220247, PMID:39495206]. FOXR2 protein abundance is constrained by PJA1-mediated ubiquitin-proteasomal degradation [PMID:33839405].","teleology":[{"year":2014,"claim":"Established FOXR2 as a bona fide oncogene and placed it functionally within SHH signaling, answering whether the gene actively drives transformation rather than being a passenger.","evidence":"Transposon insertional mutagenesis screen in mouse brain with NIH3T3 transformation, GNP proliferation, and Gli-luciferase reporter assays","pmids":["24599127"],"confidence":"High","gaps":["Did not define direct DNA-binding targets of FOXR2","Cooperation with Gli1 shown by reporter, not by genomic occupancy"]},{"year":2016,"claim":"Identified the core biochemical mechanism by showing FOXR2 forms a stable MYC/MAX complex to potentiate MYC activity, linking the oncogene to a defined transcriptional engine.","evidence":"Proteomic interaction network Co-IP/MS, functional proliferation assays, and FOXR2-knockdown xenografts","pmids":["27346356"],"confidence":"High","gaps":["Stoichiometry and structural basis of the FOXR2-MYC-MAX complex not resolved","Genome-wide consequences on MYC target genes not mapped"]},{"year":2016,"claim":"Extended FOXR2 oncogenicity to a carcinoma context and nominated β-catenin, Skp2, c-Myc, and Gli-1 as downstream effectors.","evidence":"RNAi knockdown, colony formation, xenograft, and qRT-PCR effector profiling in hepatocellular carcinoma cells","pmids":["26846213"],"confidence":"Medium","gaps":["Downstream effectors inferred from expression, not direct binding","No biochemical pathway placement"]},{"year":2017,"claim":"A series of carcinoma studies repeatedly linked FOXR2-driven proliferation and invasion to Wnt/β-catenin and Hedgehog pathway marker changes, suggesting recurrent pathway engagement across tissues.","evidence":"RNAi knockdown/overexpression with Western blot of pathway markers, cell-cycle, invasion/EMT assays, and xenografts in glioma, prostate, colorectal, and NSCLC cells","pmids":["28915588","28068638","28548041","29634928"],"confidence":"Medium","gaps":["Pathway placement based on marker correlation, not direct transcriptional or biochemical reconstitution","Whether Wnt/Hedgehog effects are direct or secondary to MYC potentiation unresolved"]},{"year":2017,"claim":"Defined post-transcriptional control of FOXR2 by demonstrating direct microRNA targeting, beginning to explain how FOXR2 levels are tuned.","evidence":"TargetScan prediction with luciferase 3'UTR reporter and Western blot of miR-202 in endometrial adenocarcinoma; later miR-152/HOTAIR axis by luciferase reporter in prostate cancer","pmids":["28827892","31269585"],"confidence":"Medium","gaps":["Physiological relevance of these miRNA axes in vivo not established","Single-lab validation"]},{"year":2019,"claim":"Provided in vivo proof that FOXR2 initiates CNS-embryonal tumors and that tumor cells possess tumor-initiating properties, moving beyond cell-line correlation.","evidence":"Transgenic Foxr2-overexpression/Trp53-knockout mouse with histology, sphere formation, transplantation, and gene expression profiling","pmids":["30976792"],"confidence":"High","gaps":["Cell of origin not precisely defined in this model","Molecular driver mechanism within the tumors not dissected"]},{"year":2021,"claim":"Showed FOXR2 stabilizes MYCN protein in neuroblastoma, providing a non-amplification route to MYCN dependence and a direct vulnerability.","evidence":"FOXR2-MYCN immunoprecipitation, knockdown with MYCN Western blot, cell-cycle/growth assays, transcriptomics, and patient tumor validation","pmids":["34110923"],"confidence":"High","gaps":["Mechanism by which FOXR2 protects MYCN from degradation not defined","Whether MYCN and MYC/MAX engagement are mutually exclusive unknown"]},{"year":2021,"claim":"Identified PJA1 as the E3 ligase controlling FOXR2 turnover, establishing how the oncoprotein's abundance is restrained.","evidence":"Co-expression, ubiquitination assay, and invasion/apoptosis assays in lung adenocarcinoma","pmids":["33839405"],"confidence":"Medium","gaps":["Ubiquitination site and degron on FOXR2 not mapped","Single-lab finding without in vivo confirmation"]},{"year":2022,"claim":"Explained how FOXR2 becomes aberrantly expressed in cancer—via hypomethylation of a novel alternative promoter—and that it co-opts ETS transcriptional circuits, unifying its pan-cancer activation mechanism.","evidence":"Pan-cancer DNA methylation analysis, functional promoter validation, knockdown proliferation readouts, and transcriptional circuit analysis across >10,000 samples","pmids":["35802025"],"confidence":"High","gaps":["What triggers promoter hypomethylation in tumors is unknown","Direct ETS partner identity not resolved"]},{"year":2024,"claim":"Placed FOXR2 mechanistically upstream of MEK/ERK by showing it suppresses the RAS inhibitor DIRAS3, and identified a druggable vulnerability.","evidence":"Human ESC-derived MGE progenitor model with FOXR2 overexpression, transcriptomics, MEK/ERK Western blot, trametinib treatment, and in vivo tumorigenicity","pmids":["39220247"],"confidence":"High","gaps":["Whether DIRAS3 suppression is a direct transcriptional effect of FOXR2 not shown","Relationship of MEK/ERK activation to MYC potentiation unclear"]},{"year":2025,"claim":"Mapped FOXR2 chromatin occupancy and demonstrated that prenatal targeting to ganglionic eminences generates tumors recapitulating NB-FOXR2 signatures, anchoring cell of origin and direct genomic targets.","evidence":"FOXR2 chromatin binding profiling, in vivo prenatal Foxr2 targeting, and single-cell transcriptomics integrated with a normal brain reference atlas in mice","pmids":["39495206"],"confidence":"High","gaps":["Direct FOXR2 consensus binding motif not fully defined","How ETS-network co-option translates to gliogenic initiation mechanistically unresolved"]},{"year":null,"claim":"How FOXR2's distinct partner engagements (MYC/MAX, MYCN stabilization, ETS circuits, DIRAS3/MEK-ERK) are integrated into a single coherent transcriptional program, and the structural basis of these interactions, remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of FOXR2 or its complexes","No unified genome-wide map reconciling MYC, ETS, and Wnt/Hedgehog outputs","Direct vs indirect nature of several pathway effects unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,13,17]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,11]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,13,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[16,4,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,8,11]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,11]}],"complexes":["MYC/MAX complex"],"partners":["MYC","MAX","MYCN","PJA1","GLI1","FUS"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6PJQ5","full_name":"Forkhead box protein R2","aliases":["Forkhead box protein N6"],"length_aa":311,"mass_kda":35.9,"function":"","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q6PJQ5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXR2","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXR2","total_profiled":1310},"omim":[{"mim_id":"300949","title":"FORKHEAD BOX R2; FOXR2","url":"https://www.omim.org/entry/300949"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"testis","ntpm":1.2}],"url":"https://www.proteinatlas.org/search/FOXR2"},"hgnc":{"alias_symbol":["MGC21658","FOXN6"],"prev_symbol":[]},"alphafold":{"accession":"Q6PJQ5","domains":[{"cath_id":"-","chopping":"9-54","consensus_level":"high","plddt":73.955,"start":9,"end":54},{"cath_id":"1.10.10.10","chopping":"190-258_266-310","consensus_level":"high","plddt":91.2469,"start":190,"end":310}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6PJQ5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6PJQ5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6PJQ5-F1-predicted_aligned_error_v6.png","plddt_mean":64.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXR2","jax_strain_url":"https://www.jax.org/strain/search?query=FOXR2"},"sequence":{"accession":"Q6PJQ5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6PJQ5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6PJQ5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6PJQ5"}},"corpus_meta":[{"pmid":"31945729","id":"PMC_31945729","title":"circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31945729","citation_count":106,"is_preprint":false},{"pmid":"30417418","id":"PMC_30417418","title":"CircABCB10 promotes nonsmall cell lung cancer cell proliferation and migration by regulating the miR-1252/FOXR2 axis.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30417418","citation_count":67,"is_preprint":false},{"pmid":"24599127","id":"PMC_24599127","title":"Identification of FoxR2 as an oncogene in medulloblastoma.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24599127","citation_count":45,"is_preprint":false},{"pmid":"27346356","id":"PMC_27346356","title":"FOXR2 Interacts with MYC to Promote Its Transcriptional Activities and Tumorigenesis.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27346356","citation_count":40,"is_preprint":false},{"pmid":"32650833","id":"PMC_32650833","title":"Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/32650833","citation_count":35,"is_preprint":false},{"pmid":"34110923","id":"PMC_34110923","title":"FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome.","date":"2021","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34110923","citation_count":33,"is_preprint":false},{"pmid":"26846213","id":"PMC_26846213","title":"FOXR2 contributes to cell proliferation and malignancy in human hepatocellular carcinoma.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26846213","citation_count":33,"is_preprint":false},{"pmid":"33536079","id":"PMC_33536079","title":"Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation.","date":"2021","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/33536079","citation_count":33,"is_preprint":false},{"pmid":"15202009","id":"PMC_15202009","title":"Identification and characterization of human FOXN6, mouse Foxn6, and rat Foxn6 genes in silico.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15202009","citation_count":30,"is_preprint":false},{"pmid":"28827892","id":"PMC_28827892","title":"miR-202 Suppresses Cell Proliferation by Targeting FOXR2 in Endometrial Adenocarcinoma.","date":"2017","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/28827892","citation_count":26,"is_preprint":false},{"pmid":"29634928","id":"PMC_29634928","title":"Down-regulation of FOXR2 inhibits non-small cell lung cancer cell proliferation and invasion through the Wnt/β-catenin signaling pathway.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29634928","citation_count":24,"is_preprint":false},{"pmid":"28548041","id":"PMC_28548041","title":"FOXR2 Promotes the Proliferation, Invasion, and Epithelial-Mesenchymal Transition in Human Colorectal Cancer Cells.","date":"2017","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/28548041","citation_count":21,"is_preprint":false},{"pmid":"30976792","id":"PMC_30976792","title":"Foxr2 promotes formation of CNS-embryonal tumors in a Trp53-deficient background.","date":"2019","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30976792","citation_count":21,"is_preprint":false},{"pmid":"35802025","id":"PMC_35802025","title":"FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35802025","citation_count":20,"is_preprint":false},{"pmid":"28068638","id":"PMC_28068638","title":"Knockdown of FOXR2 suppresses the tumorigenesis, growth and metastasis of prostate cancer.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28068638","citation_count":20,"is_preprint":false},{"pmid":"34494941","id":"PMC_34494941","title":"Circ-PGC increases the expression of FOXR2 by targeting miR-532-3p to promote the development of non-small cell lung cancer.","date":"2021","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/34494941","citation_count":17,"is_preprint":false},{"pmid":"32068268","id":"PMC_32068268","title":"Down-regulation of FOXR2 inhibits hypoxia-driven ROS-induced migration and invasion of thyroid cancer cells via regulation of the hedgehog pathway.","date":"2020","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32068268","citation_count":15,"is_preprint":false},{"pmid":"33464477","id":"PMC_33464477","title":"Long noncoding RNA LINC00520 accelerates lung adenocarcinoma progression via miR-1252-5p/FOXR2 pathway.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/33464477","citation_count":13,"is_preprint":false},{"pmid":"36107285","id":"PMC_36107285","title":"circANKRD17(has_circ_0007883) confers paclitaxel resistance of ovarian cancer via interacting with FUS to stabilize FOXR2.","date":"2022","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36107285","citation_count":13,"is_preprint":false},{"pmid":"28915588","id":"PMC_28915588","title":"FoxR2 promotes glioma proliferation by suppression of the p27 pathway.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28915588","citation_count":12,"is_preprint":false},{"pmid":"33839405","id":"PMC_33839405","title":"E3 ubiquitin ligase PJA1 regulates lung adenocarcinoma apoptosis and invasion through promoting FOXR2 degradation.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33839405","citation_count":11,"is_preprint":false},{"pmid":"36648026","id":"PMC_36648026","title":"Expanding the molecular signatures of malignant ossifying fibromyxoid tumours with two novel gene fusions: PHF1::FOXR1 and PHF1::FOXR2.","date":"2023","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/36648026","citation_count":11,"is_preprint":false},{"pmid":"31269585","id":"PMC_31269585","title":"[The mechanism of HOTAIR regulating the proliferation and apoptosis of prostate cancer cells by targeting down-regulation of miR-152 to improve the expression of FOXR2].","date":"2019","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31269585","citation_count":6,"is_preprint":false},{"pmid":"39220247","id":"PMC_39220247","title":"A human embryonic stem cell-based model reveals the cell of origin of FOXR2-activated CNS neuroblastoma.","date":"2024","source":"Neuro-oncology advances","url":"https://pubmed.ncbi.nlm.nih.gov/39220247","citation_count":5,"is_preprint":false},{"pmid":"35651928","id":"PMC_35651928","title":"FTX Regulated miR-153-3p/FOXR2 to Promote Cisplatin Resistance in Ovarian Cancer.","date":"2022","source":"Computational and mathematical methods in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35651928","citation_count":4,"is_preprint":false},{"pmid":"39866234","id":"PMC_39866234","title":"FOXR2 in cancer development: emerging player and therapeutic opportunities.","date":"2025","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/39866234","citation_count":3,"is_preprint":false},{"pmid":"37879492","id":"PMC_37879492","title":"Insights into the molecular roles of FOXR2 in the pathology of primary pediatric brain tumors.","date":"2023","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/37879492","citation_count":3,"is_preprint":false},{"pmid":"39495206","id":"PMC_39495206","title":"FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma.","date":"2025","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39495206","citation_count":2,"is_preprint":false},{"pmid":"40237561","id":"PMC_40237561","title":"FOXR2 activation is not exclusive of CNS neuroblastoma.","date":"2025","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40237561","citation_count":2,"is_preprint":false},{"pmid":"37831472","id":"PMC_37831472","title":"Combination of serum FOXR2 and transvaginal three-dimensional power Doppler ultrasonography in the diagnosis of uterine lesions.","date":"2024","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/37831472","citation_count":2,"is_preprint":false},{"pmid":"41978643","id":"PMC_41978643","title":"FOXR2-activated CNS neuroblastoma: Characterized by variable structural disruption of the FOXR2 regulatory region, recurrent copy number alterations, and elevated FOXR2 expression.","date":"2026","source":"Neuro-oncology pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/41978643","citation_count":0,"is_preprint":false},{"pmid":"39552609","id":"PMC_39552609","title":"Aggressive Malignant Ossifying Fibromyxoid Tumor With a Rare PHF1::FOXR2 Fusion: A Case Report and Literature Review.","date":"2024","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39552609","citation_count":0,"is_preprint":false},{"pmid":"41744325","id":"PMC_41744325","title":"Primary CNS Neuroblastoma, FOXR2-Activated: Clinicopathological Study of Two Cases With Immunohistochemical Characterization and Literature Review.","date":"2026","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/41744325","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18300,"output_tokens":4238,"usd":0.059235,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12277,"output_tokens":3872,"usd":0.079092,"stage2_stop_reason":"end_turn"},"total_usd":0.138327,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"FoxR2 was identified as an oncogene in medulloblastoma through a transposon mutagenesis screen; FoxR2 overexpression transformed NIH3T3 cells and promoted proliferation of granule neuron precursor (GNP) cells. FoxR2, along with Tgif2 and Alx4, activated Gli-binding sites in cooperation with Gli1, placing FoxR2 functionally within the SHH signaling pathway.\",\n      \"method\": \"Transposon-based insertional mutagenesis screen in mouse brain; NIH3T3 transformation assay; GNP proliferation assay; Gli-luciferase reporter assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays (transformation, proliferation, reporter) in a single study with in vivo genetic screen validation\",\n      \"pmids\": [\"24599127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXR2 forms a stable protein complex with MYC and MAX and promotes MYC's transcriptional activities, thereby regulating cell proliferation. This interaction was identified via large-scale proteomic analysis of the human transcription factor interaction network and validated functionally.\",\n      \"method\": \"Proteomic interaction network analysis (Co-IP/MS); functional proliferation assays; xenograft tumor growth assay with FOXR2 knockdown\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP/proteomic identification of MYC/MAX complex, combined with functional knockdown and in vivo xenograft validation in a single study\",\n      \"pmids\": [\"27346356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXR2 knockdown in hepatocellular carcinoma cells reduced cell growth and colony formation, and FOXR2 overexpression promoted xenograft tumor growth. β-catenin, Skp2, c-Myc, and Gli-1 were identified as downstream effectors of FOXR2 in regulation of cell proliferation by qRT-PCR.\",\n      \"method\": \"RNA interference knockdown; colony formation assay; xenograft mouse model; qRT-PCR of downstream effectors\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — clean KD/OE with defined cellular phenotype and downstream marker profiling, single lab, no direct biochemical pathway placement\",\n      \"pmids\": [\"26846213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In glioma cells, FoxR2 overexpression increased MMP-2 level and activity and decreased expression and nuclear accumulation of p27, promoting cell proliferation and invasion. FoxR2 knockout induced G1 arrest with decreased cyclin D1, cyclin E, and p-Rb levels.\",\n      \"method\": \"FoxR2 overexpression and knockout in glioma cell lines; Western blot for cyclin D1, cyclin E, p-Rb, p27, MMP-2; cell cycle analysis; migration/invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — defined cellular phenotype with multiple molecular readouts, single lab, no direct mechanistic reconstitution\",\n      \"pmids\": [\"28915588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXR2 knockdown in prostate cancer cells down-regulated β-catenin, cyclinD1, and c-Myc protein levels, indicating FOXR2 promotes proliferation and invasion at least in part through the Wnt/β-catenin signaling pathway.\",\n      \"method\": \"RNA interference knockdown; Western blot; in vitro proliferation, migration, invasion assays; in vivo xenograft\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — defined phenotype with pathway marker validation, single lab, no direct reconstitution\",\n      \"pmids\": [\"28068638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXR2 was identified as a direct target of miR-202 in endometrial adenocarcinoma by luciferase reporter assay; miR-202 re-expression suppressed cell proliferation and reduced FOXR2 protein levels.\",\n      \"method\": \"TargetScan prediction; luciferase reporter assay; Western blot; qRT-PCR; in vitro and in vivo proliferation assays\",\n      \"journal\": \"Disease markers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct 3'UTR luciferase validation of miR-202 targeting of FOXR2, single lab\",\n      \"pmids\": [\"28827892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXR2 knockdown in colorectal cancer cells reduced proliferation, invasion, EMT, and decreased Shh, Gli1, and Ptch1 protein expression, placing FOXR2 upstream of the Hedgehog signaling pathway in CRC.\",\n      \"method\": \"RNA interference; Western blot of Shh pathway components; in vitro invasion/EMT assays; in vivo xenograft\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — defined pathway marker changes with KD phenotype, single lab\",\n      \"pmids\": [\"28548041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXR2 knockdown inhibited non-small cell lung cancer cell proliferation and invasion, and reduced protein levels of β-catenin, cyclinD1, and c-Myc, indicating FOXR2 activates the Wnt/β-catenin pathway in NSCLC.\",\n      \"method\": \"RNA interference; Western blot; in vitro proliferation/invasion assays; in vivo xenograft\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — defined phenotype with pathway marker readout, single lab\",\n      \"pmids\": [\"29634928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Foxr2 overexpression in a Trp53-deficient mouse background caused formation of CNS-embryonal tumors in olfactory bulb and brainstem. Early proliferative lesions expanded Olig2+ cells. Tumor-derived cells formed spheres in vitro and recapitulated parental tumors upon transplantation, confirming tumor-initiating cell properties.\",\n      \"method\": \"Transgenic mouse model (Foxr2 overexpression + Trp53 knockout); histological analysis; sphere formation assay; transplantation assay; gene expression profiling\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with multiple orthogonal validations (histology, sphere assay, transplantation, transcriptomics)\",\n      \"pmids\": [\"30976792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The lncRNA HOTAIR negatively regulates miR-152, which directly targets FOXR2 3'UTR at two binding sites (validated by luciferase reporter assay). Knockdown of FOXR2 inhibited prostate cancer cell proliferation and promoted apoptosis.\",\n      \"method\": \"Luciferase reporter assay (two miR-152 binding sites on FOXR2 3'UTR); qRT-PCR; microRNA chip; CCK8/flow cytometry\",\n      \"journal\": \"Zhonghua yi xue za zhi\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct 3'UTR binding validated, functional KD phenotype shown, single lab\",\n      \"pmids\": [\"31269585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXR2 knockdown in thyroid cancer cells inhibited hypoxia-induced ROS production and migration/invasion, with the Hedgehog pathway implicated as a downstream effector mechanism.\",\n      \"method\": \"RNA interference; ROS measurement; migration/invasion assays; Hedgehog pathway inhibitor experiments\",\n      \"journal\": \"Clinical and experimental pharmacology & physiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single-method KD with partial pathway implication and no direct biochemical reconstitution\",\n      \"pmids\": [\"32068268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXR2 binds and stabilizes MYCN protein in neuroblastoma cells; FOXR2 knockdown reduced MYCN protein levels, caused cell cycle arrest, reduced cell growth, and induced cell death in FOXR2-expressing neuroblastoma cell lines.\",\n      \"method\": \"Immunoprecipitation (FOXR2-MYCN); FOXR2 knockdown in neuroblastoma cell lines; Western blot for MYCN protein; cell cycle and growth assays; transcriptome analysis\",\n      \"journal\": \"Journal of clinical oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP demonstrating FOXR2-MYCN binding, combined with KD phenotype and transcriptome profiling, validated in patient tumor samples\",\n      \"pmids\": [\"34110923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E3 ubiquitin ligase PJA1 promotes ubiquitin-mediated proteasomal degradation of FOXR2 in lung adenocarcinoma cells. Forced PJA1 expression inhibited cell invasion and induced apoptosis through inactivation of the Wnt/β-catenin signaling pathway.\",\n      \"method\": \"Co-expression studies; Western blot; ubiquitination assay; in vitro invasion and apoptosis assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — ubiquitination assay identifying PJA1 as E3 ligase for FOXR2, functional consequences shown, single lab\",\n      \"pmids\": [\"33839405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXR2 is epigenetically activated in cancer through hypomethylation of a novel alternative promoter. This novel promoter was functionally validated as necessary for FOXR2 expression and proliferation in FOXR2-expressing cancer cells. FOXR2 co-opted ETS family transcription circuits across multiple cancer lineages.\",\n      \"method\": \"Pan-cancer DNA methylation analysis; promoter methylation functional validation; FOXR2 knockdown with proliferation readout; transcriptional circuit analysis across >10,000 cancer samples\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional promoter validation combined with pan-cancer epigenetic profiling and mechanistic ETS circuit characterization across multiple cancer types\",\n      \"pmids\": [\"35802025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CircANKRD17 interacts with the RNA-binding protein FUS to stabilize FOXR2 mRNA/protein in ovarian cancer, promoting PTX resistance. This was demonstrated by RNA pull-down and RNA immunoprecipitation assays.\",\n      \"method\": \"RNA pull-down; RNA immunoprecipitation (RIP); qRT-PCR; Western blot; CCK-8; flow cytometry; xenograft\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct pull-down demonstrating circANKRD17-FUS-FOXR2 axis, single lab\",\n      \"pmids\": [\"36107285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Human FOXN6 (FOXR2) was identified as containing a forkhead (FOX) domain (codons 167-248) and a novel N-terminal FN56 domain (codons 1-69) conserved among FOXN6 and FOXN5 orthologs. The gene is located at chromosome Xp11.21, clustered with RRAGB and KLF8.\",\n      \"method\": \"Bioinformatics/in silico analysis; sequence alignment; phylogenetic analysis\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only, no functional validation\",\n      \"pmids\": [\"15202009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOXR2 overexpression in human embryonic stem cell-derived medial ganglionic eminence (MGE) progenitors activated the MEK/ERK signaling pathway through suppression of the endogenous RAS inhibitor DIRAS3, promoting proliferation and in vivo tumorigenicity. MEK inhibitor trametinib preferentially suppressed proliferation of FOXR2-expressing MGE progenitors.\",\n      \"method\": \"Human embryonic stem cell differentiation model; FOXR2 overexpression; transcriptome analysis; MEK/ERK pathway Western blot; MEK inhibitor (trametinib) treatment; in vivo tumorigenicity assay\",\n      \"journal\": \"Neuro-oncology advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway placement (FOXR2→DIRAS3 suppression→MEK/ERK activation) validated in a novel stem cell model with functional inhibitor confirmation and in vivo tumorigenicity\",\n      \"pmids\": [\"39220247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FOXR2 binding on chromatin in murine models revealed association with ETS transcriptional networks and direct binding at transcription factors coordinating initiation of gliogenesis. In vivo prenatal Foxr2 targeting to ganglionic eminences in mice induced postnatal cortical tumors recapitulating NB-FOXR2 molecular signatures.\",\n      \"method\": \"ChIP/FOXR2 chromatin binding profiling in murine models; in vivo prenatal Foxr2 targeting (electroporation/viral); single-cell transcriptomics; integration with normal brain single-cell reference atlas\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct chromatin binding profiling combined with in vivo genetic modeling and single-cell transcriptomics, multiple orthogonal methods\",\n      \"pmids\": [\"39495206\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXR2 is a forkhead transcription factor (with a canonical FOX domain and a conserved N-terminal FN56 domain, located at Xp11.21) that functions as a pan-cancer oncogene: it is epigenetically activated through hypomethylation of a novel alternative promoter, forms a stable complex with MYC/MAX to potentiate MYC transcriptional activity, binds and stabilizes MYCN protein in neuroblastoma, activates ETS transcriptional circuits and the MEK/ERK pathway (by suppressing the RAS inhibitor DIRAS3), and engages the SHH, Wnt/β-catenin, and Hedgehog pathways downstream; its protein stability is regulated by PJA1-mediated ubiquitin–proteasomal degradation, and in vivo it drives CNS-embryonal tumor formation originating from LHX6+/DLX+ medial ganglionic eminence progenitors.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXR2 is a forkhead transcription factor that functions as a pan-cancer oncogene, transforming cells and driving proliferation across diverse lineages including CNS-embryonal tumors, neuroblastoma, and multiple carcinomas [#0, #1, #13]. Its central oncogenic mechanism is the potentiation of MYC-family transcription factors: FOXR2 forms a stable complex with MYC and MAX to enhance MYC transcriptional activity [#1], and in neuroblastoma it binds and stabilizes MYCN protein, with FOXR2 loss reducing MYCN levels and triggering cell-cycle arrest and death [#11]. FOXR2 is aberrantly switched on in cancer through hypomethylation of a novel alternative promoter, and once expressed it co-opts ETS-family transcriptional circuits to sustain proliferation [#13]; chromatin-binding profiles confirm association with ETS networks and direct binding at transcription factors that initiate gliogenesis [#17]. Functionally it activates the MEK/ERK pathway by suppressing the endogenous RAS inhibitor DIRAS3, rendering FOXR2-expressing progenitors sensitive to MEK inhibition [#16]. In vivo, FOXR2 overexpression in a Trp53-deficient background or prenatal targeting to the ganglionic eminences generates CNS-embryonal/cortical tumors that recapitulate NB-FOXR2 molecular signatures, identifying medial ganglionic eminence progenitors as a cell of origin [#8, #16, #17]. FOXR2 protein abundance is constrained by PJA1-mediated ubiquitin-proteasomal degradation [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Established FOXR2 as a bona fide oncogene and placed it functionally within SHH signaling, answering whether the gene actively drives transformation rather than being a passenger.\",\n      \"evidence\": \"Transposon insertional mutagenesis screen in mouse brain with NIH3T3 transformation, GNP proliferation, and Gli-luciferase reporter assays\",\n      \"pmids\": [\"24599127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define direct DNA-binding targets of FOXR2\", \"Cooperation with Gli1 shown by reporter, not by genomic occupancy\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified the core biochemical mechanism by showing FOXR2 forms a stable MYC/MAX complex to potentiate MYC activity, linking the oncogene to a defined transcriptional engine.\",\n      \"evidence\": \"Proteomic interaction network Co-IP/MS, functional proliferation assays, and FOXR2-knockdown xenografts\",\n      \"pmids\": [\"27346356\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of the FOXR2-MYC-MAX complex not resolved\", \"Genome-wide consequences on MYC target genes not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended FOXR2 oncogenicity to a carcinoma context and nominated β-catenin, Skp2, c-Myc, and Gli-1 as downstream effectors.\",\n      \"evidence\": \"RNAi knockdown, colony formation, xenograft, and qRT-PCR effector profiling in hepatocellular carcinoma cells\",\n      \"pmids\": [\"26846213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors inferred from expression, not direct binding\", \"No biochemical pathway placement\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A series of carcinoma studies repeatedly linked FOXR2-driven proliferation and invasion to Wnt/β-catenin and Hedgehog pathway marker changes, suggesting recurrent pathway engagement across tissues.\",\n      \"evidence\": \"RNAi knockdown/overexpression with Western blot of pathway markers, cell-cycle, invasion/EMT assays, and xenografts in glioma, prostate, colorectal, and NSCLC cells\",\n      \"pmids\": [\"28915588\", \"28068638\", \"28548041\", \"29634928\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathway placement based on marker correlation, not direct transcriptional or biochemical reconstitution\", \"Whether Wnt/Hedgehog effects are direct or secondary to MYC potentiation unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined post-transcriptional control of FOXR2 by demonstrating direct microRNA targeting, beginning to explain how FOXR2 levels are tuned.\",\n      \"evidence\": \"TargetScan prediction with luciferase 3'UTR reporter and Western blot of miR-202 in endometrial adenocarcinoma; later miR-152/HOTAIR axis by luciferase reporter in prostate cancer\",\n      \"pmids\": [\"28827892\", \"31269585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of these miRNA axes in vivo not established\", \"Single-lab validation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided in vivo proof that FOXR2 initiates CNS-embryonal tumors and that tumor cells possess tumor-initiating properties, moving beyond cell-line correlation.\",\n      \"evidence\": \"Transgenic Foxr2-overexpression/Trp53-knockout mouse with histology, sphere formation, transplantation, and gene expression profiling\",\n      \"pmids\": [\"30976792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell of origin not precisely defined in this model\", \"Molecular driver mechanism within the tumors not dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed FOXR2 stabilizes MYCN protein in neuroblastoma, providing a non-amplification route to MYCN dependence and a direct vulnerability.\",\n      \"evidence\": \"FOXR2-MYCN immunoprecipitation, knockdown with MYCN Western blot, cell-cycle/growth assays, transcriptomics, and patient tumor validation\",\n      \"pmids\": [\"34110923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which FOXR2 protects MYCN from degradation not defined\", \"Whether MYCN and MYC/MAX engagement are mutually exclusive unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified PJA1 as the E3 ligase controlling FOXR2 turnover, establishing how the oncoprotein's abundance is restrained.\",\n      \"evidence\": \"Co-expression, ubiquitination assay, and invasion/apoptosis assays in lung adenocarcinoma\",\n      \"pmids\": [\"33839405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site and degron on FOXR2 not mapped\", \"Single-lab finding without in vivo confirmation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Explained how FOXR2 becomes aberrantly expressed in cancer—via hypomethylation of a novel alternative promoter—and that it co-opts ETS transcriptional circuits, unifying its pan-cancer activation mechanism.\",\n      \"evidence\": \"Pan-cancer DNA methylation analysis, functional promoter validation, knockdown proliferation readouts, and transcriptional circuit analysis across >10,000 samples\",\n      \"pmids\": [\"35802025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What triggers promoter hypomethylation in tumors is unknown\", \"Direct ETS partner identity not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed FOXR2 mechanistically upstream of MEK/ERK by showing it suppresses the RAS inhibitor DIRAS3, and identified a druggable vulnerability.\",\n      \"evidence\": \"Human ESC-derived MGE progenitor model with FOXR2 overexpression, transcriptomics, MEK/ERK Western blot, trametinib treatment, and in vivo tumorigenicity\",\n      \"pmids\": [\"39220247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DIRAS3 suppression is a direct transcriptional effect of FOXR2 not shown\", \"Relationship of MEK/ERK activation to MYC potentiation unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Mapped FOXR2 chromatin occupancy and demonstrated that prenatal targeting to ganglionic eminences generates tumors recapitulating NB-FOXR2 signatures, anchoring cell of origin and direct genomic targets.\",\n      \"evidence\": \"FOXR2 chromatin binding profiling, in vivo prenatal Foxr2 targeting, and single-cell transcriptomics integrated with a normal brain reference atlas in mice\",\n      \"pmids\": [\"39495206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXR2 consensus binding motif not fully defined\", \"How ETS-network co-option translates to gliogenic initiation mechanistically unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FOXR2's distinct partner engagements (MYC/MAX, MYCN stabilization, ETS circuits, DIRAS3/MEK-ERK) are integrated into a single coherent transcriptional program, and the structural basis of these interactions, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of FOXR2 or its complexes\", \"No unified genome-wide map reconciling MYC, ETS, and Wnt/Hedgehog outputs\", \"Direct vs indirect nature of several pathway effects unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 13, 17]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 13, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16, 4, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 8, 11]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 11]}\n    ],\n    \"complexes\": [\"MYC/MAX complex\"],\n    \"partners\": [\"MYC\", \"MAX\", \"MYCN\", \"PJA1\", \"GLI1\", \"FUS\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":6,"faith_total":6,"faith_pct":100.0}}